# DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

> **NCT03599518** · PHASE1 · TERMINATED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** DS-1205c
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03599518
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-21
- **Primary completion:** 2020-04-22
- **Final completion:** 2020-06-29
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** This study was terminated based on a business decision by the Sponsor.
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03599518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03599518, "DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03599518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*